Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01... von Mittendorf, Elizabeth A, Clifton, Guy T, Holmes, Jarrod P, Clive, Kevin S, Patil, Ritesh, Benavides, Linda C, Gates, Jeremy D, Sears, Alan K, Stojadinovic, Alexander, Ponniah, Sathibalan, Peoples, George E

Volltext

Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer von Wiseman, Charles L., Holmes, Jarrod P., Calfa, Carmen, Dakhil, Shaker R., Bhattacharya, Saveri, Peoples, George E., Lacher, Markus D., Lopez-Lago, Miguel, Kharazi, Alex, Del Priore, Giuseppe, Chang, Mingjin, Adams, Daniel L., Williams, William V.

Volltext

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast canc... von Chick, R. Connor, Clifton, G. Travis, Hale, Diane F., Vreeland, Timothy J., Hickerson, Annelies T., Kemp Bohan, Phillip M., McCarthy, Patrick M., Litton, Jennifer K., Alatrash, Gheath, Murthy, Rashmi K., Qiao, Na, Philips, Anne, Lukas, Jason, Holmes, Jarrod P., Mittendorf, Elizabeth A., Peoples, George E.

Volltext

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Gro... von Peoples, George E, Holmes, Jarrod P, Hueman, Matthew T, Mittendorf, Elizabeth A, Amin, Asna, Khoo, Steven, Dehqanzada, Zia A, Gurney, Jennifer M, Woll, Michael M, Ryan, Gayle B, Storrer, Catherine E, Craig, Dianna, Ioannides, Constantin G, Ponniah, Sathibalan

Volltext

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with... von Clifton, G. Travis, Peace, Kaitlin M., Holmes, Jarrod P., Vreeland, Timothy J., Hale, Diane F., Herbert, Garth S., Litton, Jennifer K., Murthy, Rashmi K., Lukas, Jason, Peoples, George E., Mittendorf Elizabeth, A.

Volltext

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 von BENAVIDES, Linda C, GATES, Jeremy D, PEOPLES, George E, CARMICHAEL, Mark G, PATEL, Ritesh, HOLMES, Jarrod P, HUEMAN, Matthew T, MITTENDORF, Elizabeth A, CRAIG, Dianna, STOJADINOVIC, Alexander, PONNIAH, Sathibalan

Volltext

Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients von Carmichael, Mark G., Benavides, Linda C., Holmes, Jarrod P., Gates, Jeremy D., Mittendorf, Elizabeth A., Ponniah, Sathibalan, Peoples, George E.

Volltext

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine von HOLMES, Jarrod P, BENAVIDES, Linda C, PONNIAH, Sathibalan, PEOPLES, George E, GATES, Jeremy D, CARMICHAEL, Mark G, HUEMAN, Matthew T, MITTENDORF, Elizabeth A, MURRAY, James L, AMIN, Asna, CRAIG, Dianna, VON HOFE, Eric

Volltext

The E75 HER2/neu peptide vaccine von Mittendorf, Elizabeth A., Holmes, Jarrod P., Ponniah, Sathibalan, Peoples, George E.

Volltext

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials G... von Carmichael, Mark G, Benavides, Linda C, Holmes, Jarrod P, Gates, Jeremy D, Mittendorf, Elizabeth A, Ponniah, Sathibalan, Peoples, George E

Volltext

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer von Clifton, G Travis, Hale, Diane, Vreeland, Timothy J, Hickerson, Annelies T, Litton, Jennifer K, Alatrash, Gheath, Murthy, Rashmi K, Qiao, Na, Philips, Anne V, Lukas, Jason J, Holmes, Jarrod P, Peoples, George E, Mittendorf, Elizabeth A

Volltext

Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions von Tyler, Timothy, Stojanoff, Erik, Cannon, Joan, Um, Jessie J, Young, Stacia, Holmes, Jarrod P, Brent, Lonnie D, Martin, Nancy

Volltext

The GP2 peptide: A HER2/neu-based breast cancer vaccine von Clive, Kevin S., Tyler, Josh A., Clifton, G. Travis, Holmes, Jarrod P., Ponniah, Sathibalan, Peoples, George E., Mittendorf, Elizabeth A.

Volltext

Use of Booster Inoculations to Sustain the Clinical Effect of an Adjuvant Breast Cancer Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 von HOLMES, Jarrod P, CLIFTON, Guy T, PATIL, Ritesh, BENAVIDES, Linda C, GATES, Jeremy D, STOJADINOVIC, Alexander, MITTENDORF, Elizabeth A, PONNIAH, Sathibalan, PEOPLES, George E

Volltext

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 von Holmes, Jarrod P, Gates, Jeremy D, Benavides, Linda C, Hueman, Matthew T, Carmichael, Mark G, Patil, Ritesh, Craig, Dianna, Mittendorf, Elizabeth A, Stojadinovic, Alexander, Ponniah, Sathibalan, Peoples, George E

Volltext

Circulating regulatory T cells (CD4+ CD25+ FOXP3+ ) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/ neu (AE37) peptide von Gates, Jeremy D, Clifton, Guy T, Benavides, Linda C, Sears, Alan K, Carmichael, Mark G, Hueman, Matthew T, Holmes, Jarrod P, Jama, Yusuf H, Mursal, Mohamed, Zacharia, Athina, Ciano, Kathy, Khoo, Steven, Stojadinovic, Alexander, Ponniah, Sathibalan, Peoples, George E

Volltext

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine von Holmes, Jarrod P., Clifton, Guy T., Patil, Ritesh, Benavides, Linda C., Gates, Jeremy D., Stojadinovic, Alexander, Mittendorf, Elizabeth A., Ponniah, Sathibalan, Peoples, George E.

Volltext

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37) von Mittendorf, Elizabeth A, Holmes, Jarrod P, Murray, James L, von Hofe, Eric, Peoples, George E

Volltext

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Ca... von Amin, Asna, Benavides, Linda C., Holmes, Jarrod P., Gates, Jeremy D., Carmichael, Mark G., Hueman, Matthew T., Mittendorf, Elizabeth A., Storrer, Catherine E., Jama, Yusuf H., Craig, Dianna, Stojadinovic, Alex, Ponniah, Sathibalan, Peoples, George E.

Volltext

CD4+ T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37) von Mittendorf, Elizabeth A, Holmes, Jarrod P, Murray, James L, von Hofe, Eric, Peoples, George E

Volltext